Multiplex genome engineering using CRISPR/Cas systems.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 23287718.
- Also identified by DOI 10.1126/science.1231143 and PMC identifier 3795411.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Functional elucidation of causal genetic variants and elements requires precise genome editing technologies. The type II prokaryotic CRISPR (clustered regularly interspaced short palindromic repeats)/Cas adaptive immune system has been shown to facilitate RNA-guided site-specific DNA cleavage. We engineered two different type II CRISPR/Cas systems and demonstrate that Cas9 nucleases can be directed by short RNAs to induce precise cleavage at endogenous genomic loci in human and mouse cells. Cas9 can also be converted into a nicking enzyme to facilitate homology-directed repair with minimal mutagenic activity. Lastly, multiple guide sequences can be encoded into a single CRISPR array to enable simultaneous editing of several sites within the mammalian genome, demonstrating easy programmability and wide applicability of the RNA-guided nuclease technology.
Medical subject headings
- CRISPR-Cas Systems
- DNA Cleavage
- Genetic Engineering
- Genome
- Inverted Repeat Sequences
- Microarray Analysis